PMID- 10897414
OWN - NLM
STAT- MEDLINE
DCOM- 20001016
LR  - 20180815
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 479
DP  - 2000
TI  - Activation of cytosolic phospholipase A2 by opsonized zymosan in human 
      neutrophils requires both ERK and p38 MAP-kinase.
PG  - 115-23
AB  - The present study demonstrates that stimulation of human neutrophils with 
      opsonized zymosan (OZ), which binds to Fc gamma receptors (Fc gamma Rs) and C3b 
      receptors, activates both ERK and p38 MAP-kinase. Thus, the relative role of both 
      types of MAP-kinase, ERK and p38, in activation of cPLA2 by OZ was studied. cPLA2 
      activation by OZ was detected 15 sec after stimulation, maintained a plateau for 
      10 min and decreased thereafter. p38 MAP-kinase activation exhibited kinetics 
      similar to that of cPLA2, while ERK activation was detected within 15 sec but 
      decreased significantly in less than 5 min after stimulation. Pretreatment of the 
      cells with the MEK inhibitor, PD-098059, or the p38 MAP-kinase inhibitor, 
      SB-203580 resulted in total inhibition of ERK or p38 MAP-kinase activity, 
      respectively. Each inhibitor caused a partial inhibition during the time course 
      of cPLA2 activity, while their combination caused a total inhibition. Compared to 
      OZ, inactivated OZ, which does not contain the complement proteins, induced an 
      identical time-dependent stimulation of ERK and p38 MAP-kinase as well as a 
      similar cPLA2 activity, suggesting that the role of the C3b receptors in this 
      system is negligible. It is concluded that OZ activates both ERK and p38 
      MAP-kinase and that the two isotypes are required for the onset and maintenance 
      of cPLA2 activity.
FAU - Hazan-Halevy, I
AU  - Hazan-Halevy I
AD  - Department of Clinical Biochemistry, Faculty of Health Sciences, Ben-Gurion 
      University, Negev and Soroka Medical Center, Beer-Sheva, Israel.
FAU - Levy, R
AU  - Levy R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Flavonoids)
RN  - 0 (Imidazoles)
RN  - 0 (Pyridines)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - EC 3.1.1.32 (Phospholipases A)
RN  - EC 3.1.1.4 (Phospholipases A2)
RN  - OU13V1EYWQ (SB 203580)
RN  - SJE1IO5E3I (2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one)
SB  - IM
MH  - Cytosol/enzymology
MH  - Enzyme Activation
MH  - Enzyme Inhibitors/pharmacology
MH  - Flavonoids/pharmacology
MH  - Humans
MH  - Imidazoles/pharmacology
MH  - Kinetics
MH  - Mitogen-Activated Protein Kinases/*blood
MH  - Neutrophils/*enzymology
MH  - Phospholipases A/*blood
MH  - Phospholipases A2
MH  - Pyridines/pharmacology
MH  - p38 Mitogen-Activated Protein Kinases
EDAT- 2000/07/18 11:00
MHDA- 2000/10/21 11:01
CRDT- 2000/07/18 11:00
PHST- 2000/07/18 11:00 [pubmed]
PHST- 2000/10/21 11:01 [medline]
PHST- 2000/07/18 11:00 [entrez]
AID - 10.1007/0-306-46831-X_10 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2000;479:115-23. doi: 10.1007/0-306-46831-X_10.